ClinicaliQ Trial Snapshot
- A Study of JNJ-64042056 in Participants With Preclinical Alzheimer’s Disease — Active Not Recruiting • Phase II • Neurology • NCT06544616.
- An experimental drug tested to see if it slows tau protein buildup in early Alzheimer's disease using brain scanning.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to assess whether JNJ-64042056 affects the spread and build up of tau (a protein in brain) when compared with placebo, using brain scan (tau PET) to determine results from specific areas of the brain. Conditions: Alzheimer Disease Interventions: JNJ-64042056, Placebo Lead Sponsor: Janssen Pharmaceutica N.V., Belgium Planned Enrollment: 55 participants